Filing Details

Accession Number:
0001609351-16-000073
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-07-19 16:23:11
Reporting Period:
2016-07-15
Filing Date:
2016-07-19
Accepted Time:
2016-07-19 16:23:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609351 Spark Therapeutics Inc. ONCE Biological Products, (No Disgnostic Substances) (2836) 462654405
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610381 Rogerio Coelho Vivaldi C/O Spark Therapeutics, Inc.
3737 Market Street, Suite 1300
Philadelphia PA 19104
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-07-15 1,000 $3.45 19,716 No 4 M Direct
Common Stock Acquisiton 2016-07-15 1,000 $3.45 20,716 No 4 M Direct
Common Stock Acquisiton 2016-07-15 5,000 $7.50 25,716 No 4 M Direct
Common Stock Disposition 2016-07-15 5,600 $52.96 20,116 No 4 S Direct
Common Stock Disposition 2016-07-15 1,400 $53.32 18,716 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2016-07-15 1,000 $0.00 1,000 $3.45
Common Stock Stock Option (right to buy) Disposition 2016-07-15 1,000 $0.00 1,000 $3.45
Common Stock Stock Option (right to buy) Disposition 2016-07-15 5,000 $0.00 5,000 $7.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
9,116 2024-06-10 No 4 M Direct
10,203 2024-08-11 No 4 M Direct
155,186 2024-12-01 No 4 M Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 16, 2015.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.25 to $53.24, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.25 to $53.50, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
  4. This option was granted on June 10, 2014 and vests over four years, with 25% of the shares underlying the option vesting on April 1, 2015 and the remainder vesting quarterly thereafter.
  5. This option was granted on August 11, 2014 and vests over four years with 25% of the shares underlying the option vesting on May 24, 2015 and the remainder vesting quarterly thereafter.
  6. This option was granted on December 1, 2014 and vests over four years, with 25% of the shares underlying the option vesting on April 1, 2015 and the remainder vesting quarterly thereafter.